A Delphi developed syllabus for the medical specialty of sport and exercise medicine: Part 2

David Humphries^{1,2}, Rod Jaques^{3,4}, H Paul Dijkstra^{5,6}, Irfan M Asif⁷, Mark Batt^{8,4}, Mats Borjesson⁹, Emin Ergen¹⁰, Celeste Geertsema¹¹, Boris Gojanovic¹², Anca Ionescu¹³, Christa Janse Van Rensburg¹⁴, Connie Lebrun¹⁵, Nahar Azmi Mohamed¹⁶, Margot Mountjoy¹⁷, Tvisha Parikh¹⁸, Diana Robinson¹⁹, Robert Sallis²⁰, Martin Schwellnus²¹, Padraig Sheeran²².

¹School of Medicine, University of Tasmania, Hobart, Tasmania, Australia

² ACSEP, Melbourne, Australia, Past President

³English Institute of Sport, London, UK

⁴ FSEM(UK), Past President

⁵ Department of Medical Education, Aspetar Sports Medicine and Orthopedic Hospital, Doha, Qatar

⁶ Department for Continuing Education, University of Oxford, Oxford, UK

⁷ Department of Family and Community Medicine, University of Alabama, Birmingham (UAB) School of Medicine, USA

⁸ Nottingham University Hospitals / Centre for Sport, Exercise & Osteoarthritis Research Versus Arthritis, Nottingham, UK

⁹ Center for Health and Performance, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

¹⁰ Department of Sports Medicine, Aspetar Sports Medicine and Orthopedic Hospital, Doha, Qatar

¹¹ Department of Sports Medicine, Aspetar Sports Medicine and Orthopedic Hospital, Doha, Qatar

- ¹² Swiss Olympic Medical Center, Hôpital de La Tour, Meyrin, Switzerland
- ¹³ Sports Medicine Department, Carol Davila University of Medicine, Bucharest, Romania

¹⁴ Sport Exercise Medicine and Lifestyle Institute (SEMLI) & Section Sports Medicine, Faculty

of Health Sciences, University of Pretoria, Pretoria, South Africa

¹⁵ Department of Family Medicine, Faculty of Medicine & Dentistry, University of Alberta, Canada

¹⁶ Sports Medicine Department, University Malaya Medical Center, Kuala Lumpur, Malaysia

¹⁷ Department of Family Medicine, McMaster University, Hamilton, Canada

¹⁸ Sir HN Reliance Foundation Hospital, Girgaum, Mumbai, India

¹⁹ ACSEP, Melbourne, Australia. Curriculum Committee Chair

²⁰ Kaiser Permanente Medical Center, Fontana, California, USA

²¹ Faculty of Health Sciences, University of Pretoria, South Africa

²² Faculty of SEM RCSI RCPI, Dublin, Ireland. Past Dean

Corresponding Author

Dr David Humphries: 36 Collins Street, Hobart 7000, Australia. Telephone +61362319225 Email: <u>david.humphries@utas.edu.au</u>

Abstract

Background

Training in the medical specialty of sport and exercise medicine (SEM) is available in many, but not all countries. In 2015 an independent Delphi group, the international syllabus in sport and exercise medicine group (ISSEMG), was formed to create a basic syllabus for this medical specialty. The group provided the first part of this syllabus, by identifying 11 domains and a total of 80 general learning areas for the specialty, in December 2017. The next step in this process, and the aim of this paper was to determine the specific learning areas for each of the 80 general learning areas.

Methods and Findings

A group of 26 physicians with a range of primary medical specialty qualifications including, Sport and Exercise Medicine, Family Medicine, Internal Medicine, Cardiology, Rheumatology, and Anaesthetics were invited to participate in a multiple round online Delphi study to develop specific learning areas for each of the previously published general learning areas. All invitees have extensive clinical experience in the broader sports medicine field, and in one or more components of sports medicine governance at national and/or international level.

Conclusion

The hierarchical syllabus developed by the ISSEMG provides a useful resource in the planning, development, and delivery of specialist training programs in the medical specialty of sport and exercise medicine.

Introduction

The purpose of the international syllabus in sport and exercise medicine group (ISSEMG) has been detailed in the initial paper[1]. Briefly it was determined that, while there was a need to increase the numbers of sport and exercise medicine (SEM) physicians internationally, there were potential barriers to the development of SEM training in countries without training programs, one of which was the requirement to develop a syllabus. The creation of a basic international syllabus for the medical specialty of SEM was seen as a solution to that barrier, and the ISSEMG has undertaken the development of this syllabus. Of note the World Health Organisation (WHO) has issued a global action plan on physical activity [2], the recommendations of which can only emphasise the need for more SEM specialists. The aim of this international Delphi consensus was to agree on the specific learning areas for each of the 80 previously agreed general learning areas of the 11 domains in the medical specialty of SEM. There has been no change in the purpose, focus or funding of the project since the first publication.

Methods

As detailed in the initial paper[1] the ISSEMG decided on a hierarchical syllabus structure, comprising broad domains of learning, for example the domain "Physical activity and human

health". Each domain was broken into general learning areas, for example in the physical activity and human health domain "Applied exercise physiology: types of exercise, effects of exercise and maximising adaptations to exercise" and "Physical activity guidelines and recommendations" are amongst the general learning areas. This publication details the third level of the hierarchy, namely the specific learning areas under each general learning areas. The project has continued to use a modified Delphi process. The members of the Delphi group were invited to be part of process on the basis that they had significant skills in one or more of the following; SEM syllabus and/or curriculum development, SEM training program development and/or implementation, and SEM specialist assessment program development and/or implementation. Four additional members (EE, CG, AI, and CL) were added to the group involved in the original paper to broaden representation, and one member of the original team was replaced by two others late in the process because of a scheduled academic hand over. For each set of specific learning areas an initial questionnaire, a commentary and 1-2 follow up questionnaires have been used to determine which specific learning areas would be included in the syllabus. When required email discussions initiated by group members assisted the process. A total of 24 questionnaires were used in the development of the specific learning areas. The response rates to guestionnaires varied between 55% and 100%, with the overall average response rate being 65%. A cut point of 80% agreement amongst the respondents to each questionnaire was used to indicate group agreement for inclusion in all but 4 cases. In these cases, as indicated in the specific learning areas list with an asterisk, 79% was accepted. The lack of 100% response rate was recognised as a potential weakness in the methodology. This was, in part, addressed by the fact that all members of the group were made aware of the results of the initial round scores for each topic as part of the follow up commentary. All members of the group were able to provide additional commentary at that point and were able to respond to follow up questionnaires on the same topic.

Results

The domain, general and specific learning areas for the SEM specialty syllabus are presented in a numbered tabular form for ease of use and cross referencing.

Each specific learning area represents an area of medical knowledge determined by the ISSEMG to be fundamental to medical specialists in the specialty of SEM. Some are relatively broad areas of knowledge, some quite specific. ISSEMG also added specific learning areas to the previously uncategorised 'Advanced skills' group. These are learning areas which may be regarded as advanced learning in the specialty, pertinent to some but possibly not all national medical organisations seeking to train in the specialty. These are now listed in the 'Extrinsic skills of a SEM physician' domain. Each Domain, General learning area and Specific learning area has been listed in a numerical structure to assist with understanding the overall syllabus and to allow easy referencing. Additional comments, agreed by the ISSEMG, have been added in some sections to enhance the document. In a number of instances there have been minor adjustments to the titles and numbering of the general learning areas in this paper compared to the original paper[1]. These have been made to assist with the clarity and utility of the syllabus. These changes are noted where they have occurred.

Domain	General Learning Areas	Specific Learning Areas
1. Physical activity and human health	1.1 The role of physical activity in the prevention and treatment of disease: population health perspectives	 1.1.1 Physical activity levels as a modifiable factor in population health 1.1.2 Determinants of physical activity participation in different populations 1.1.3 The health burden of preventable and modifiable non communicable diseases 1.1.4 Preventable and modifiable non communicable diseases that are influenced by physical activity 1.1.5 Effective physical activity interventions in improving population health 1.1.6 Barriers to implementation of physical activity programs for population health
	1.2 Applied exercise physiology: types of exercise, effects of exercise, and maximising adaptations to exercise	 1.2.1 Aerobic exercise: Physiological effects, adaptations and testing methods 1.2.2 Anaerobic exercise: Physiological effects, adaptations and testing methods 1.2.3 Strength training: Physiological effects, adaptations and testing methods 1.2.4 Proprioceptive training: Physiological effects, adaptations and testing methods 1.2.5 Flexibility training: Physiological effects, adaptations and testing methods 1.2.6 Endurance training: Physiological effects, adaptations and testing methods 1.2.7 Energy transfer during physical activity 1.2.8 The physiological basis, effectiveness, and application of recovery strategies both short and long term
	1.3 Physical activity guidelines and recommendations	 1.3.1 Relevant national and international physical activity and sedentary behaviour guidelines 1.3.2 Proportion of population that meet physical activity and sedentary behaviour guidelines 1.3.3 Health risks of not achieving minimum physical activity and sedentary behaviour guidelines 1.3.4 Health benefits of achieving minimum physical activity and sedentary behaviour guidelines 1.3.5 Health benefits of achieving physical activity levels beyond minimum physical activity and sedentary behaviour guidelines
	1.4 Barriers to physical activity: environmental, social, physical and psychological	 1.4.1 Climatic context including pollution, temperature, and altitude 1.4.2 Social and financial context, including poverty and lack of facilities 1.4.3 Cultural context, including clothing, tradition, and religion 1.4.4 Personal identification context including gender 1.4.5 Physical ability context, including pre-existing illness and injury 1.4.6 Psychological context, including motivational issues, and pre-existing mental health disorders
	1.5 Screening before prescribing exercise	1.5.1 When medical evaluation is appropriate1.5.2 When medical evaluation is mandatory1.5.3 General medical evaluation

F		
	(Please note that for clarity	1.5.4 Musculoskeletal evaluation
	the single general learning	1.5.5 Cardiorespiratory evaluation
	area 1.5 in the original	1.5.6 Neurological evaluation
	paper has been split into	
	two general learning areas,	
	1.5 and 1.6, in this paper.	
	This numerical change	
	flows on for the remainder	
	of this domain)	
	1.6 Contra-indications in	1.6.1 Relative and absolute contraindications in
	exercise prescription	cardiovascular disease
		1.6.1 Relative and absolute contraindications in
		neurological disease
		1.6.3 Relative and absolute contraindications in
		respiratory disease
		1.6.4 Relative and absolute contraindications in
		musculoskeletal disease
		1.6.5 Relative and absolute contraindications in
		immunological and haematological disease
	1.7 Exercise prescription in	1.7.1 Benefits of exercise prescription in healthy
	healthy individuals	individuals
		1.7.2 Role of health professionals in exercise
		prescription in healthy individuals
		1.7.3 Motivational interviewing and creating
		behavioural change
		1.7.4 Structured exercise prescription options
		1.7.5 Exercise types: modalities, frequency, intensity,
		duration, adaptation rates and risks
	1.0 Evereice proceduling in	1.7.6 The intersection of SEM and the fitness industry
	1.8 Exercise prescription in	1.8.1 Specific benefits of exercise over a range of
	individuals with disease	diseases
		1.8.2 Problem oriented exercise prescription
		1.8.3 Systematic exercise prescription protocols
		1.8.4 Other health professionals and exercise
		prescription
		1.8.5 Exercise types: modalities, frequency, intensity,
		duration, adaptation rates, review schedules and
		risks
		1.8.6 Effective interaction between health
		professionals and fitness industry professionals
		1.8.7 Integration of exercise prescription with other
		health interventions including nutritional advice
	1.9 Exercise prescription in	1.9.1 Exercise prescription in pregnancy
	special circumstances	1.9.2 Exercise prescription in those of advanced age
		1.9.3 Exercise prescription in children
		1.9.4 Exercise prescription in novice exercisers
		1.9.5 Exercise prescription for overweight and obese
		individuals
		1.9.6 Exercise prescription pre- and post- surgery
	1.10 Communicating the	1.10.1 Role of the SEM specialist in promotion of
	physical activity message	physical activity to the government
	beyond the individual	1.10.2 Role of the SEM specialist in promotion of
	,	physical activity to communities
		1.10.3 Role of the SEM specialist in advocacy for
		exercise facilities
	1	

		1.10.4 Role of the SEM specialist in promotion of
		physical activity to other health professionals
2. Medical issues	2.1 Neurological issues	2.1.1 Exercise induced headache
related to exercise	related to physical activity	2.1.2 Post-concussion syndrome
		2.1.3 Epilepsy and physical activity
		2.1.4 Peripheral neuropathy
		2.1.5 Nerve entrapments
		Comment: A SEM physician should recognise that
		exercise may reveal underlying disease and have a
		robust clinical approach to neurological symptoms
		presenting in a SEM setting, including but not limited
		to muscle cramping, weakness, extremity pain,
		sensory alteration, and loss of neuromuscular co-
		ordination
	2.2 Respiratory issues	2.2.1 Exercise induced bronchospasm
	related to physical activity	2.2.2 Asthma and exercise
		2.2.3 Other environment related triggers for
		bronchospasm and asthma when exercising,
		including pollutants
		2.2.4 Asthma medications and the WADA list
		2.2.5 Pulmonary embolus
		2.2.6 Lung restriction due to musculoskeletal disease
		including but not limited to ankylosing spondylitis
		2.2.7 Upper and lower respiratory tract infections
		Comment: A SEM physician should recognise that
		exercise may reveal underlying disease and have a
		robust clinical approach to respiratory symptoms
		presenting in a SEM setting including but not limited
		to cough, wheeze, environmental respiratory triggers,
		pre-syncope, and shortness of breath
	2.3 Cardiovascular issues	2.3.1 Athlete's heart, adaptive cardiac changes
	related to physical activity	related to exercise
		2.3.2 Sudden cardiac death in athletes
		2.3.3 Exercise and cardiac ischaemic events
		2.3.4 Ventricular pre-excitation syndrome
		2.3.5 Anomalous coronary arteries
		2.3.6 Channelopathies
		2.3.7 Marfan syndrome
		2.3.8 Cardiomyopathies
		2.3.9 Hypertension
		2.3.10 Endocarditis, myocarditis, and pericarditis
		2.3.11 Cardiac valvular disease
		2.3.12 Atherosclerotic coronary artery disease 2.3.13 Extreme endurance events as a cardiac
		stressor
		2.3.14 Exercise related peripheral vascular occlusive conditions
		2.3.15 Deep vein thrombosis
		Comment: A SEM physician should recognise that
		exercise may reveal underlying disease and have a
		robust clinical approach to cardiovascular symptoms
		presenting in a SEM setting, including but not limited

	to short noin shortness of breath unevposted
	to chest pain, shortness of breath, unexpected
2.4 Contraintentingliggues	fatigue, dizziness, palpations, syncope, and collapse
2.4 Gastrointestinal issues	2.4.1 Runner's diarrhoea
related to physical activity	2.4.2 Exercise related gastro-oesophageal reflux
	2.4.3 Anti-inflammatory drugs and gastrointestinal
	pathology
	2.4.4 Irritable bowel syndrome
	2.4.5 Inflammatory bowel disease
	2.4.6 Exercise induced abdominal pain, acute and
	chronic
	2.4.7 Gastrointestinal bleeding and ischaemia in
	endurance athletes
	2.4.8 Impaired nutritional absorption and its
	consequences
	Comment: A SEM physician should recognise that
	exercise may reveal underlying disease and have a
	robust clinical approach to gastrointestinal symptoms
	presenting in a SEM setting including but not limited
	to nausea, a changing bowel habit, abdominal pain,
	and bloating
2.5 Renal and urogenital	2.5.1 Contact sport and the single kidney
issues related to physical	2.5.2 Electrolyte disturbance related to physical
activity	activity
	2.5.3 Renal disease, hydration, and physical activity
	2.5.4 Haemoglobinuria, proteinuria and
	myoglobinuria in athletes
	2.5.6 Renal and urogenital infections
	2.5.7 Urogenital microtrauma and its consequences
	including but not limited to infection, skin lesions,
	testicular and neurological pathologies
	Comments A CEM physician should recognize that
	Comment: A SEM physician should recognise that
	exercise may reveal underlying disease and have a
	robust clinical approach to renal and
	urogenital symptoms presenting in a SEM setting
	including but not limited to haematuria, proteinuria,
	and sexual dysfunction
2.6 Metabolic issues related	2.6.1 Diabetes
to physical activity	2.6.2 Metabolic syndrome
	2.6.3 Thyroid and parathyroid disease
	2.6.4 Bone density issues in athletes
	2.6.5 Vitamin D deficiency
	2.6.6 The athlete with fatigue (including over-
	reaching and over-training)
	Comment: A SEM physician should recognise that
	exercise may reveal underlying disease and have a
	robust clinical approach to metabolic symptoms
	presenting in a SEM setting including but not limited
	to excessive fatigue, unexplained weight gain or loss,
	amenorrhoea, thermal intolerance, palpitations,
	hypoglycaemia, and hyperglycaemia
2.7 Ear, nose and throat	2.7.1 Vocal cord dysfunction
issues related to physical	2.7.2 Otic barotrauma and infection in sport
activity	2.7.3 Allergic rhinitis

		2.7.4 Sinusitis, pharyngitis, and tonsillitis
	2.8 Immunological and	2.8.1 The effects of physical activity on immune
	haematological issues	function (both positive and negative)
	related to physical activity	2.8.2 Anaphylaxis
		2.8.3 Exercise induced urticaria
		2.8.4 Exercise induced angioedema and anaphylaxis
		2.8.5 Haemodilution in athletes
		2.8.6 Iron status and physical activity
		2.8.7 Anaemias
		2.8.8 Clotting disorders
		2.8.9 Sickle cell trait and other haemoglobinopathies
		Comment: A SEM physician should recognise that
		exercise may reveal underlying disease and have a
		robust clinical approach to immunological and
		haematological symptoms presenting in a SEM
		setting including but not limited to fatigue, excessive
		bruising, recurrent infection, skin rashes and
		recurrent allergic problems
<u> </u>	2.9 Dermatological issues	2.9.1 Blisters and other skin trauma related to
	related to physical activity	physical activity
		2.9.2 Skin and subcutaneous infection in athletes
		2.9.3 Eczema and dermatitis
		2.9.4 Skin cancer
		2.9.5 Herpes gladiatorum
		2.9.6 Sunburn
		2.9.7 Stump/Prosthesis interfaces in athletes with
		artificial limbs
		Comment: A SEM physician should recognise that
		exercise may reveal underlying disease and have a
		robust clinical approach to dermatological symptoms
		presenting in a SEM setting including but not limited
		to urticarial and infectious rashes, changes in
		pigmentation and purpura
	2.10 Psychological and	2.10.1 Competition related anxiety
	mental health issues	2.10.2 Athletic life demands and stress related illness
	related to physical activity	2.10.3 Masking and self-management of mental
		health issues with exercise
		2.10.4 Anorexia nervosa, bulimia, disordered eating,
		and exercise addiction
		2.10.5 Transition to retirement mental health issues
		2.10.6 Anxiety, depression, psychosis, and bipolar
		disease
		2.10.7 Sleep hygiene, in and out of competition
		2.10.8 Basic sports psychology including, but not
		limited to, performance and psychological responses
		to injury
3. Injuries related to	3.1 Principles of tissue	3.1.1 Overuse and traumatic mechanisms of tissue
sport and exercise	injury and repair in the	injury
1	musculoskeletal system	3.1.2 Acute and chronic inflammation in connective
		tissues
		3.1.3 Connective tissue repair: regeneration, healing,
		fibrosis, and pathological repair
		3.1.4 Adaptive properties of connective tissues to
		training stress
	1	training 5tr 035

	2.2 Drippintes of internet	2.2.1 Intrincia and outside the factor is the stiff of the
	3.2 Principles of injury	3.2.1 Intrinsic and extrinsic risk factor identification
	prevention	3.2.2 Gender, and age variation and injury risk in
		sport
		3.2.3 Psychological variation and injury risk in sport
		3.2.4 The influence of prior injury on future injury risk
		3.2.5 Sport specific preparation
		3.2.6 Biomechanical assessment of gait, and sport
		specific activity e.g. throwing
		3.2.7 Injury prevention equipment including, but not
		limited to, footwear, helmets, eye protection and
		braces
		3.2.8 Proven injury risk reduction programs
		3.2.9 Implementation of injury risk reduction
		programs
		3.2.10 Current injury prediction and prevention
	2.2 Company and half my of	models, and their limitations
	3.3 General pathology of	3.3.1 Rheumatological disease presenting in a SEM
	the musculoskeletal system	setting
		3.3.2 Inheritable connective tissue variants and
		disorders, e.g. hypermobility syndrome, and their
		contribution to injury risk in a SEM setting
	3.4 Management of head	3.4.1 Management of head and neck skeletal injury
	and neck injuries in SEM	3.4.2 Management of head and neck neurological
	(Diagon moto title strength	injury
	(Please note title change	3.4.3 Management of cervical spine disc, ligament,
	compared to the initial	and joint injury
	paper)	3.4.4 Management of injury to the eyes, ears, nose,
		and oral structures
		3.4.5 Appropriate collaboration with other specialists
	2.5 Managament of upper	in the management of these injuries
	3.5 Management of upper	3.5.1 Management of upper limb skeletal injury
	limb injuries in SEM	3.5.2 Management of upper limb joint injury
	(Plassa poto titlo change	3.5.3 Management of upper limb tendon pathology
	(Please note title change compared to the initial	3.5.4 Management of upper limb muscular injury
		3.5.5 Management of upper limb neurological injury
	paper)	
		3.5.6 Appropriate collaboration with other specialists
	2.6 Management of chect	in the management of these injuries
	3.6 Management of chest wall, abdominal wall, and	3.6.1 Management of chest wall and thoracic spine
		skeletal injury *
	thoracic spine injuries in	3.6.2 Management of chest wall and thoracic spine
	SEM	disc, ligament, and joint injury * 3.6.3 Management of chest and abdominal wall
	(Plaasa pata titla change	
	(Please note title change	muscular injury 3.6.4 Commotio cordis
	compared to the initial paper)	3.6.5 Appropriate collaboration with other specialists
	2.7 Management of lumber	in the management of these injuries
	3.7 Management of lumbar spine and pelvic injuries in	3.7.1 Management of lumbar spine and pelvis skeletal injury
	SEM	3.7.2 Management of lumbar spine and pelvis disc,
		ligament, and joint injury
	(Please note title change	3.7.3 Management of lumbar spine and pelvis
	compared to the initial	muscular injury
	paper)	3.7.4 Appropriate collaboration with other specialists in the management of these injuries
1		In the management of these injunes

	3.8 Management of lower limb injuries in SEM (Please note title change compared to the initial paper)	 3.8.1 Management of lower limb skeletal injury 3.8.2 Management of lower limb tendon pathology 3.8.3 Management of lower limb muscular injury 3.8.4 Management of lower limb neurological injury * 3.8.5 Appropriate collaboration with other specialists in the management of these injuries
	3.9 Interpretation of radiological and other investigations	 3.9.1 Appropriate use, and recognition of strengths and weaknesses, of X-rays, CT scans, ultrasound scans, isotope scans and MRI scans in a SEM setting 3.9.2 Principles of interpretation of radiological examinations 3.9.3 Appropriate use, and recognition of strengths and weaknesses, of laboratory testing in a SEM setting 3.9.4 Appropriate use, and recognition of strengths and weaknesses, of dynamometry and other forms of strength testing in a SEM setting
		Comment: Interpretation of point of care ultrasound scans relevant to SEM may be included as an advanced specific learning area
	3.10 Principles of injury rehabilitation 3.11 Return to sport decision making	 3.10.1 Early rehabilitation including protection, optimal loading, compression, and elevation 3.10.2 Management of pain and the inflammatory response 3.10.3 Restoration of joint range of motion and stability 3.10.4 Restoration of muscular flexibility, strength, and endurance 3.10.5 Restoration of proprioception and balance 3.10.6 Sport specific functional activities 3.10.7 Mitigation of underlying risk factors 3.10.8 The physiology and mitigation of deconditioning 3.10.9 Psychological aspects of injury 3.10.11 Interdisciplinary care 3.11.1 The return to sport continuum 3.11.2 Athlete autonomy
	decision making	 3.11.2 Athlete autohomy 3.11.3 Strengths and weaknesses of physical testing in return to play decision making 3.11.4 Psychological influences in return to play decision making 3.11.5 Third party influences in return to play decision making 3.11.6 Current models in return to play decision making
4. Nutrition	4.1 Sports nutrition for health and performance	 4.1.1 The influence of nutrition on the health of athletes 4.1.2 The influence of nutrition on athletic performance 4.1.3 Recognition and utilisation of the skills of qualified sports dieticians 4.1.4 Problems that may arise as a consequence of dietary restrictions

		4.1.5 Interdisciplinary management of athletes with
		significant nutritional problems
		4.1.6 Current controversies in athlete nutrition and
		assisting athletes to evaluate various sources of
		information concerning these issues
		4.1.7 The influence of nutrition on the health of
		young and developing athletes, especially during the
		growth spurt
	4.2 Hydration	4.2.1 Recommendations for fluid intake in the
		general and athletic populations
		4.2.2 Evaluation of the hydration status of athletes
		4.2.3 Hydration protocols according to type and
		duration of activities
		4.2.4 The effects of hydration choices in the potential
		development of pathological states
		4.2.5 The impact of variables such as temperature
		and electrolyte concentration on fluid absorption
		from the gut
	4.3 Carbohydrates	4.3.1 Recommendations for dietary carbohydrate
	ne carbonyarates	intake in the general and athletic populations
		4.3.2 Types and quality of dietary carbohydrates
		4.3.3 The differing roles of carbohydrates in athletes
		at different phases of the training and competition
		cycle
	4.4 Fats	4.4.1 Recommendations for dietary fat intake in the
	4.4 Γαιδ	5
		general and athletic populations
		4.4.2 The various types of dietary fats and their
	4.5. Drotoin	effects on human health and athletic performance
	4.5 Protein	4.4.1 Recommendations for dietary protein intake in
		the general and athletic populations
		4.5.2 The difference between high- and low-quality
		protein
		4.5.3 The role of protein intake at different phases of
		the training and competition cycle
	4.6 Micronutrients and	4.6.1 Recommendations for micronutrient and
	vitamins	vitamin intake in the general and athletic populations
		4.6.2 Dietary choices and disease states that may
		compromise the micronutrient and vitamin status of
		an athlete
		4.6.3 Clinical presentations, methods of evaluating
		and methods of correcting micronutrient and vitamin
		disturbance in an athlete
	4.7 Energy requirements	4.7.1 Energy requirements of athletes of various
	and relative energy	types
	deficiency	4.7.2 Athletes at risk of problems with energy
1	deficiency	4.7.2 Athletes at risk of problems with energy
	denciency	balance
	deficiency	
	deficiency	balance
	denciency	balance 4.7.3 Short- and long-term pathological consequences and clinical presentations of athletes
	denciency	balance 4.7.3 Short- and long-term pathological consequences and clinical presentations of athletes with relative energy deficiency
	denciency	balance 4.7.3 Short- and long-term pathological consequences and clinical presentations of athletes with relative energy deficiency 4.7.4 Management of athletes with relative energy
	denciency	balance 4.7.3 Short- and long-term pathological consequences and clinical presentations of athletes with relative energy deficiency 4.7.4 Management of athletes with relative energy deficiency
	denciency	 balance 4.7.3 Short- and long-term pathological consequences and clinical presentations of athletes with relative energy deficiency 4.7.4 Management of athletes with relative energy deficiency 4.7.5 Identification, evaluation, and treatment of
		 balance 4.7.3 Short- and long-term pathological consequences and clinical presentations of athletes with relative energy deficiency 4.7.4 Management of athletes with relative energy deficiency 4.7.5 Identification, evaluation, and treatment of relative energy deficiency in an interdisciplinary
		balance 4.7.3 Short- and long-term pathological consequences and clinical presentations of athletes with relative energy deficiency 4.7.4 Management of athletes with relative energy deficiency 4.7.5 Identification, evaluation, and treatment of relative energy deficiency in an interdisciplinary setting
		 balance 4.7.3 Short- and long-term pathological consequences and clinical presentations of athletes with relative energy deficiency 4.7.4 Management of athletes with relative energy deficiency 4.7.5 Identification, evaluation, and treatment of relative energy deficiency in an interdisciplinary

4.8 Nutritional supplements 4.8 The scientific rationale behind the use of various nutritional supplements 4.8 Nutritional supplements 4.8.2 The health risks of nutritional supplements 4.8.2 The health risks of nutritional supplements 4.8.3 The risks of committing an 'Anti-doping Rule Violation' via supplement usage, and appropriate sources of information to minimise this risk diction to a variety of permitted medications commonly prescribed to athletes including but not limited to analgesics, non-steroidal anti-inflammatories, corticosteroid injections, inhaled bronchodilators, sleeping tablets and anxiolytic agents 5.1 Medication abuse in elite athletes 5.1.1 Merisks of and anxiolytic agents 5.1.2 Appropriate prescription of medications required for management of injuries and medical conditions, after a formal consultation with the athlete 5.1.3 The risks of providing excessive quantities of medications to a thiefes 5.1.4 Ther ole of the SEM physician in avoiding the prescription of medication via third parties such as training and allied health staff without the specific direction of population in athletes 5.2 The influence of medication via and intrates 5.2.1 Identification of population in athletes 5.2 The influence of medication via and intrates 5.2.1 Identification and intrates 5.2.4 Potential risks of medication via and intrates 5.2.1 Identification and intrates 5.2.3 Medication and exercise induced hypoglycaemia in patients using medications used in the development of indone prologoy 5.3.1 Exe			that may act as general biomarkers for overall
5. Pharmacology 5.1 Medication abuse in elite athletes 3.3 The risks of nutritional supplements 4.8.2 The health risks of nutritional applements 4.8.3 The risks of committing an 'Anti-doping Rule Violation' via supplement usage, and appropriate sources of information to minimise this risk ources of information to minimise this risk sources of information to minimise this risk sources of information to minimise this risk or a variety of permitted medications commonly prescribed to athletes including but not limited to analgesics, non-steroidal anti-inflammatories, corticosteroid injections, inhaled bronchodilators, sleeping tablets and anxiolytic agents 5.1.2 Appropriate prescription of medications required for management of injuries and medical conditions, after a formal consultation with the athlete 5.1.3 The risk of providing excessive quantities of medications to athletes 5.1.4 The role of the SEM physician in avoiding the prescription of medication via third parties such as training and allied health staff without the specific direction of the physician 5.1.5 Strategies to minimise the potential long-term health risks of medication in athletes 5.2 The influence of exercise capacity 5.2.1 Gentification of population groups in which medications used in the treatment of disease on exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.3 Medication and exercise interactions which may cause or worsen disease 5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, praminitide, exenatide and long acting sufforylureras 5.3.3 The risk of the combination of prolonged exercise and NSAIDS receingent disease 5.3.3 The risk of the combination of prolon			5 6
4.8.2 The health risks of nutritional supplements 4.8.3 The risks of committing an 'Anti-doping Rule Violation 'via supplement usage, and appropriate sources of information to minimise this risk 5. Pharmacology 5.1 Medication abuse in elite athletes 5.1.2 Mapporpriate prescription of medications commonly prescribed to athletes including but not limited to analgesics, non-steroidal anti-inflammatories, corticosteroid injections, inhaled bronchodilators, sleeping tablets and anxiolytic agents 5.1.2 Appropriate prescription of medications in an modical conditions, after a formal consultation with the athlete 5.1.3 The risk of providing excessive quantities of medication in athletes 5.2 The influence of medication sused in the treatment of disease on exercise capacity 5.2 The influence of medication sused in the treatment of disease on exercise capacity is most likely to occur 5.2 A Potential risks posed by flooroguinolones and renin angiotens in the development of tendon pathology 5.3 Medication and exercise interactions which may cause or worsen disease 5.3 Medication and exercise interactions which may cause or worsen disea		4.8 Nutritional supplements	4.8.1 The scientific rationale behind the use of
5. Pharmacology 5.1 Medication abuse in elite athletes 4.8.3 The risks of committing an 'Anti-doping Rule Violation' via supplement usage, and addiction to a variety of permitted medications commonly rescribed to athletes including but not limited to analgesics, non-steroidal anti-inflammatories, corticosteroid injections, inhaled bronchodilators, sleeping tablets and anxiolytic agents 5.12 Appropriate prescription of medications commonly rescribed to athletes including but not limited to analgesics, non-steroidal anti-inflammatories, corticosteroid injections, inhaled bronchodilators, sleeping tablets and anxiolytic agents 5.12 Appropriate prescription of medications with the athlete 5.1.3 The risk of providing excessive quantities of medications to athletes 5.1.4 The role of the SEM physician in avoiding the prescription of medication with the pathete 5.1.3 The role of the SEM physician in avoiding the prescription of medication used in the treatment of disease on exercise capacity 5.2 The influence of medications used in the treatment of disease on exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Medication and exercise interactions which may influence sercise interactions which may cause or worsen disease 5.3 Medication and exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramilintide, exentide and long acting sulfonylureas 5.3 Medication and exercise interactions which may realises in the development of tendon pathology 5.3.3 The risk of the combination of exercise and NSAIDS causing renal disease <t< th=""><th></th><th></th><th>various nutritional supplements</th></t<>			various nutritional supplements
5. Pharmacology 5.1 Medication abuse in elite athletes 5.1.1 The risks of excessive use, abuse, and addiction to a variety of permitted medications commonly prescribed to athletes including but not limited to analgesics, non-steroidal anti-inflammatorices, corticosteroid injections, inhaled bronchodilators, sleeping tablets and anxiolytic agents 5.1.2 Appropriate prescription of medications required for management of injuries and medical conditions, after a formal consultation with the athlete 5.1.3 The risk of providing excessive quantities of medications to athletes 5.2.4 The influence of medications used in the treatment of disease on exercise capacity 5.2.5.2 The influence of medications used in the treatment of disease on exercise capacity 5.2.5.3 Medication and exercise capacity 5.3 Medication and exercise interactions which may cause or worsen disease 5.3 Medication and exercise interactions which may cause or worsen disease 5.3 The risk of the combination of exercise and NSAUS causing or worsening real disease and straining busices and intrates 5.3 Medication and exercise interactions which may cause or worsen disease 5.3 Therick of the combination of exercise and NSAUS causing or worsening real disease 5.3.3 The risk of the combination of prolonged exercise and NSAUS causing or worsening real disease 5.3.3 The risk of the combination of prolonged exercise and NSAUS precipitating hyponatemia 5.3.4 Drugs which impair thermorequiation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism's by which this			4.8.2 The health risks of nutritional supplements
sources of information to minimise this risk 5. Pharmacology 5.1 Medication abuse in elite athletes 5.1.1 The risks of excessive use, abuse, and addiction to a variety of permitted medications commonly prescribed to athletes including but not limited to analgesics, non-steroidal anti-inflammatories, corticosteroid injections, inhaled bronchoollators, sleeping tablets and anxiolytic agents 5.1.2 Appropriate prescription of medications required for management of injuries and medical conditions, after a formal consultation with the athlete 5.1.3 The risk of providing excessive quantities of medications to athletes 5.1.4 The risk of providing excessive quantities of medications used in the treatment of disease on exercise capacity 5.2 The influence of medications used in the treatment of disease on exercise capacity 5.2.1 A bill influence of exercise capacity 5.2.2 A potential risks of medications which medication sused in the treatment of disease on exercise capacity 5.2.3 Risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology 5.3 Medication and exercise interactions which may cause or worsen disease 5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, praminitide, exenatide and NSAIDS causing or worsening real disease 5.3.3 The risk of the combination of exercise and NSAIDS causing or worsening real disease			4.8.3 The risks of committing an 'Anti-doping Rule
5. Pharmacology 5.1 Medication abuse in elite athletes 5.1.1 The risks of excessive use, abuse, and addiction to a variety of permitted medications commonly prescribed to athletes including but not limited to analgesics, non-steroid anti-inflammatories, corticosteroid injections, inhaled bronchodilators, sleeping tablets and anxiolytic agents 5.1.2 Appropriate prescribed to athletes including but not limited to analgesics, non-steroid injections, inhaled bronchodilators, sleeping tablets and anxiolytic agents 5.1.2 Appropriate prescription of medications required for management of injuries and medical conditions, after a formal consultation with the athlete 5.1.3 The risk of providing excessive quantities of medications to athletes 5.1.4 The role of the SEM physician in avoiding the prescription of medication in athletes 5.2 The influence of medications used in the treatment of disease on exercise capacity 5.2.2 Cardiac medications which may influence exercise capacity is most likely to occur 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of renducing bit polygolycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramilintide, exenatide and long acting sufforylureas 5.3.3 The risk of the combination of perolonged exercise and NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS recipital phyponatermia 5.3.4 Drugs which limis thermoregulation including anticholinergics, alcohoh, opiates, n			Violation' via supplement usage, and appropriate
 elite athletes to a variety of permitted medications commonly prescribed to athletes including but not limited to analgesics, non-steroidal anti-inflammatories, corticosteroid injections, inhaled bronchodilators, sleeping tablets and anxiolytic agents 5.1.2 Appropriate prescription of medications required for management of injuries and medical conditions, after a formal consultation with the athlete 5.1.3 The risk of providing excessive quantities of medications to athletes 5.1.4 The role of the SEM physician in avoiding the prescription of medication via third parties such as training and allied health staff without the specific direction of the physician 5.2 The influence of medications used in the treatment of disease on exercise capacity 5.2.1 Identification of population groups in which medications and intrates 5.2.2 Cardiac medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.3 The cink of the combination of exercise and NSAIDS causing or worsening real disease 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening insulin, pramilitide, exenatide and long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening insule, noreludation anticholinergics, alcohol, opiates, neuroleptic drugs, antichories, alcohol, opiates, neuroleptic drugs, 			sources of information to minimise this risk
5.2 The influence of medications used in the treatment of disease on exercise capacity 5.1 Identification of population groups in which medications or the physician is 2.2 Cardiac medications which medications used in the treatment of disease on exercise capacity 5.2 The influence of medications are exercise capacity 5.2.1 Identification of population groups in which medications of the physician is 2.2 Cardiac medications which medications and medications used in the treatment of disease on exercise capacity 5.3 Medication and exercise interactions which may cause or worsen disease 5.3.3 The risk of the combination of exercise and NSAIDS causing or worsening real disease on exercise interactions which may cause or worsen disease 5.3 The influence of medications used in the treatment of disease on exercise capacity 5.2.1 Identification of population groups in which medications used in the treatment of disease on exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.3.3 The risk of the combination of exercise and NSAIDS causing or worsening real disease 5.3.3 The risk of the combination of exercise and NSAIDS causing or worsening real disease 5.3.3 The risk of the combination of exercise and NSAIDS causing or worsening real disease 5.3.1 Carcia checians designed to reduce blood glucose levels including insulin, pramilitide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of exercise and NSAIDS causing or worsening real disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS causing or worsening real disease	5. Pharmacology	5.1 Medication abuse in	5.1.1 The risks of excessive use, abuse, and addiction
inalgesics, non-steroidal anti-inflammatories, corticosteroid injections, inhaled bronchodilators, sleeping tablets and anxiolytic agents 5.1.2 Appropriate prescription of medications required for management of injuries and medical conditions, after a formal consultation with the atthlete 5.1.3 The risk of providing excessive quantities of medications to athletes 5.1.4 The role of the SEM physician in avoiding the prescription of medication via third parties such as training and allied health staff without the specific direction of the physician 5.2 The influence of medications used in the treatment of disease on exercise capacity 5.2 The influence of medication or adtively influencing exercise capacity in the treatment of disease on exercise capacity 5.2 The influence of medication and usercise interactions which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.2 A Potential risks posed by fluoroquinolones and renin anglotensin II receptor antagonists in the development of tendon pathology 5.3 Medication and exercise interactions which may cause or worsen disease 5.3.1 Fixercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramilintide, exenatide and long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatemia 5.3.4 Drugs which impair thermoregulation including antich		elite athletes	to a variety of permitted medications commonly
corticosteroid injections, inhaled bronchodilators, sleeping tablets and anxiolytic agents 5.1.2 Appropriate prescription of medications required for management of injuries and medical conditions, after a formal consultation with the athlete 5.1.3 The risk of providing excessive quantities of medications to athletes 5.1.4 The role of the SEM physician in avoiding the prescription of medication via third parties such as training and allied health staff without the specific direction of the physician 5.1.5 Strategies to minimise the potential long-term health risks of medication in athletes5.2 The influence of medications used in the treatment of disease on exercise capacity5.2.1 Identification of population groups in which medication patholity influencing exercise capacity is most likely to occur5.2 Addition and exercise interactions which may cause or worsen disease5.3.1 Kercise induced hypoglycaemia in patients using medications designed to reduce blood glucose tevels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of prolonged exercise and NSAIDS receipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, anticholinergics, alcohol, opiates, neuroleptic drugs, anticholinerg			prescribed to athletes including but not limited to
sleeping tablets and anxiolytic agents5.12 Appropriate prescription of medications required for management of injuries and medical conditions, after a formal consultation with the athlete5.1.3 The risk of providing excessive quantities of medications to athletes5.1.4 The role of the SEM physician in avoiding the prescription of medication via third parties such as training and allied health staff without the specific direction of the physician 5.1.5 Strategies to minimise the potential long-term health risks of medication in athletes5.2 The influence of medications used in the treatment of disease on exercise capacity5.2.1 The influencing exercise capacity is most likely to occur5.2 Cardiac medication swhich may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Medication and exercise interactions which may cause or worsen disease5.3 Medication and exercise interactions which may cause or worsen disease5.3 Medication and exercise interactions which may cause or worsen disease5.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoreguiation including anticholinergics, alcohol, opiates, neuroleptic drugs, anticholinergics, alcohol, opia			analgesics, non-steroidal anti-inflammatories,
5.1.2 Appropriate prescription of medications required for management of injuries and medical conditions, after a formal consultation with the athlete5.1.3 The risk of providing excessive quantities of medications to a thletes 5.1.4 The role of the SEM physician in avoiding the prescription of medication via third parties such as training and allied health staff without the specific direction of the physician 5.1.5 Strategies to minimise the potential long-term health risks of medication in athletes5.2 The influence of medications used in the treatment of disease on exercise capacity5.2.1 Identification of population groups in which medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.3.1 Exercise induced hypougraemia in patients using medications designed to reduce blood glucose levels including insulin, pramilintide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of prolonged exercise and NSAIDS causing or worsening renal disease5.3 A Drugs which impair thermoregulation including antichelpressants, and the mechanisms's by which this			corticosteroid injections, inhaled bronchodilators,
required for management of injuries and medical conditions, after a formal consultation with the athlete5.1.3 The risk of providing excessive quantities of medications to athletes5.1.4 The role of the SEM physician in avoiding the prescription of medication via third parties such as training and allied health staff without the specific direction of the physician5.2 The influence of medications used in the treatment of disease on exercise capacity5.2 The influence of medication sused in the treatment of disease on exercise capacity5.2.1 Identification of population groups in which medication sused in the treatment of disease on exercise capacity5.2.2 Cardiac medications which may including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risk posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease6.3 Medication and exercise interactions which may cause or worsen disease5.3.2 The risk of the combination of exercise and NAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, acohol, opiates, neuroleptic drugs, anticholinergics, and the mechanism/s by which this			
conditions, after a formal consultation with the athlete5.1.3 The risk of providing excessive quantities of medications to athletes5.2 The influence of medications used in the treatment of disease on exercise capacity5.2 The influence of medications used in the 			5.1.2 Appropriate prescription of medications
athlete5.15.2 The influence of medications used in the treatment of disease on exercise capacity5.3 Medication and exercise interactions which may cause or worsen disease5.3 Medication and exercise and NSAIDS causing or worsening renal disease5.3 Medication and exercise interactions which may cause or worsen disease5.3 Medication and exercise and NSAIDS causing or worsening renal disease5.3 The risk of the combination of exercise and NSAIDS causing or worsening renal disease5.3 The risk of the combination of prolonged exercise and NSAIDS causing or worsening renal disease5.3 The risk of the combination of prolonged exercise and NSAIDS causing or worsening renal disease5.3 The risk of the combination of prolonged exercise and NSAIDS causing or worsening renal disease5.3 The risk of the combination of prolonged exercise and NSAIDS causing or worsening renal disease5.3 The risk of the combination of prolonged exercise and NSAIDS causing or worsening renal disease5.3 The risk of the combin			
5.1.3 The risk of providing excessive quantities of medications to athletes 5.1.4 The role of the SEM physician in avoiding the prescription of medication via third parties such as training and allied health staff without the specific direction of the physician 5.1.5 Strategies to minimise the potential long-term health risks of medication in athletes5.2 The influence of medications used in the treatment of disease on exercise capacity5.2.1 Identification of population groups in which medication negatively influencing exercise capacity is most likely to occur 5.2.2 Cardiac medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of percense and NSAIDS causing or vorsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermorequiation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
medications to athletes5.14 The role of the SEM physician in avoiding the prescription of medication via third parties such as training and alled health staff without the specific direction of the physician 5.1.5 Strategies to minimise the potential long-term health risks of medication in athletes5.2 The influence of medications used in the treatment of disease on exercise capacity5.2.1 Identification of population groups in which medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramilintide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of exercise and NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS recipitating hyponatremia 5.3.4 Drugs which this			athlete
5.1.4 The role of the SEM physician in avoiding the prescription of medication via third parties such as training and allied health staff without the specific direction of the physician 5.1.5 Strategies to minimise the potential long-term health risks of medication in athletes5.2 The influence of medications used in the treatment of disease on exercise capacity5.2.1 Identification of population groups in which medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.3.1 Exercise induced hypoglycaemia in patients using medication of exercise and NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS causing or worsening renal disease 5.3.4 Drugs which this			
prescription of medication via third parties such as training and allied health staff without the specific direction of the physician 5.1.5 Strategies to minimise the potential long-term health risks of medication in athletes5.2 The influence of medications used in the treatment of disease on exercise capacity5.2.1 Identification of population groups in which medication negatively influencing exercise capacity is most likely to occur5.2.2 Cardiac medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of prolonged exercise and NSAIDS recipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
training and allied health staff without the specific direction of the physician 5.1.5 Strategies to minimise the potential long-term health risks of medication in athletes5.2 The influence of medications used in the treatment of disease on exercise capacity5.2.1 Identification of population groups in which medication negatively influencing exercise capacity is most likely to occur5.2.2 Cardiac medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of prolonged exercise and NSAIDS causing or worsening renal disease 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
direction of the physician 5.1.5 Strategies to minimise the potential long-term health risks of medication in athletes5.2 The influence of medications used in the treatment of disease on exercise capacity5.2.1 Identification of population groups in which medication negatively influencing exercise capacity is most likely to occur5.2.2 Cardiac medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of prolonged exercise and NSAIDS causing or worsening renal disease 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
5.1.5 Strategies to minimise the potential long-term health risks of medication in athletes5.2 The influence of medications used in the treatment of disease on exercise capacity5.2.1 Identification of population groups in which medication support in the treatment of disease on exercise capacity5.2.2 Cardiac medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of exercise and NSAIDS causing or worsening renal disease5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
bealth risks of medication in athletes5.2 The influence of medications used in the treatment of disease on exercise capacity5.2.1 Identification of population groups in which medication negatively influencing exercise capacity is most likely to occur5.2.2 Cardiac medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of prolonged exercise and NSAIDS causing or worsening renal disease5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
5.2 The influence of medications used in the treatment of disease on exercise capacity5.2.1 Identification of population groups in which medication negatively influencing exercise capacity is most likely to occur5.2.2 Cardiac medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of prolonged exercise and NSAIDS causing or worsening renal disease 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
 medications used in the treatment of disease on exercise capacity medication negatively influencing exercise capacity is most likely to occur 5.2.2 Cardiac medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.3 Medication and exercise interactions which may cause or worsen disease 5.3 Cause or worsen disease 5.3 Therisk of the combination of exercise and NSAIDS causing or worsening renal disease 5.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3 A Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this 			
treatment of disease on exercise capacitymost likely to occur5.2.2 Cardiac medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of exercise and NSAIDS causing or worsening renal disease5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
exercise capacity5.2.2 Cardiac medications which may influence exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.3 The risk of the combination of exercise and NSAIDS causing or worsening renal disease5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
 exercise capacity and the mechanisms responsible, including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology 5.3 Medication and exercise interactions which may cause or worsen disease 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism's by which this 			
 including but not limited to beta blockers, diuretics, ACE inhibitors and nitrates 5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology 5.3 Medication and exercise interactions which may cause or worsen disease 5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this 		exercise capacity	
ACE inhibitors and nitrates5.2.3 Risks posed by some lipid lowering agents to skeletal muscle5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
5.2.3 Risks posed by some lipid lowering agents to skeletal muscle 5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
skeletal muscle5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
5.2.4 Potential risks posed by fluoroquinolones and renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
renin angiotensin II receptor antagonists in the development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
development of tendon pathology5.3 Medication and exercise interactions which may cause or worsen disease5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
 5.3 Medication and exercise interactions which may cause or worsen disease 5.3.1 Exercise induced hypoglycaemia in patients using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this 			· · ·
exercise interactions which may cause or worsen disease using medications designed to reduce blood glucose levels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this		5.3 Medication and	
may cause or worsen diseaselevels including insulin, pramlintide, exenatide and long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
disease long acting sulfonylureas 5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
5.3.2 The risk of the combination of exercise and NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this		5	
NSAIDS causing or worsening renal disease 5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
5.3.3 The risk of the combination of prolonged exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
exercise and NSAIDS precipitating hyponatremia 5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
5.3.4 Drugs which impair thermoregulation including anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			1 0
anticholinergics, alcohol, opiates, neuroleptic drugs, antidepressants, and the mechanism/s by which this			
antidepressants, and the mechanism/s by which this			
			impairment occurs
5.3.5 The risk of exercise induced dehydration			
altering the blood concentrations of various drugs			
including novel anticoagulants			
5.3.6 The potential for prolongation of the QT			
interval in susceptible individuals when taking various			

		drugs and drug combinations including but not
		limited to macrolide antibiotics
6. Anti-Doping	6.1 The World Anti-Doping Agency (WADA) list (Please note title change compared to the initial paper)	 6.1.1 The roles of the World Anti-Doping Agency (WADA) 6.1.2 The 4 main categories of prohibited substances in the WADA list 6.1.3 The 3 criteria for a drug or method to be entered in the WADA list, and recognise that a drug or method must meet at least 2 of the 3 criteria to be prohibited 6.1.4 The differences between the WADA categories of 'prohibited at all times', 'prohibited in competition' and 'prohibited in certain sports' 6.1.5 The 10 categories of Anti-Doping Rule Violation that apply to athletes and support staff 6.1.6 Sources of additional information regarding whether a drug or method is prohibited by the WADA list, including but not limited to "http://www.globaldro.org" 6.1.7 The doping risks posed by supplements and information provision to athletes encompassing consideration of i) actual need/benefit ii) possible risk to health and iii) risk of inadvertent doping 6.1.8 The date on which the WADA list is updated
		annually 6.1.9 The roles and responsibilities of the athlete under the WADA code
	6.2 The WADA therapeutic use exemption process	 6.2.1 The role of the therapeutic use exemption process in the management of legitimate medical conditions in athletes 6.2.2 The therapeutic use exemption process should generally not be used when an appropriate non-prohibited option exists 6.2.3 Circumstances where a therapeutic use exemption is required prior to an athlete commencing treatment with a prohibited substance or method 6.2.4 Circumstances where a retroactive therapeutic use exemption may be sought for an athlete using a prohibited substance or method 6.2.5 The bodies that grant therapeutic use exemptions and which body to apply to in each circumstance 6.2.6 The non-ethical use of the therapeutic use exemption process 6.2.7 Application for a therapeutic use exemption, forms and procedures 6.2.8 The appeals process for a disallowed therapeutic use exemption request
	6.3 Other prohibited medications in specific sports	 6.3.1 Recognition that some professional athletes, including jockeys, are subject to a set of anti-doping rules unrelated to the WADA rules and the specialised knowledge required when dealing with such athletes 6.3.2 Recognition that some sports do not allow the use of specific substances/medications/methods in

		addition to the standard WADA prohibitions and
		research any such additional restrictions whenever
		taking on a role with an unfamiliar sport
	6.4 The consequences of	6.4.1 The key roles a specialist sport and exercise
	6.4 The consequences of doping: Health risks, sanctions, and responsibilities	 6.4.1 The key roles a specialist sport and exercise medicine physician has in the anti-doping arena and the methods that may be used to subvert those roles 6.4.2 Effective communication of the complexities of the anti-doping rules, sanctions, and responsibilities to athletes and sports officials 6.4.3 The principle that the athlete always has absolute responsibility for any substance they ingest or administer 6.4.4 The health risks, both short and long term, of the various doping methods and medications. In particular, the risks of anabolics, stimulants, and the manipulation of hormones, hormone agonists and haemoglobin levels. 6.4.5 Effective communication of doping health risk information to athletes and officials 6.4.6 Ways in which anti-doping rule violations can be committed
		 6.4.7 Anti-doping rules which apply to different sports leagues/disciplines 6.4.8 The potential legal and criminal consequences of doping violations 6.4.9 Co-ordinated anti-doping information for sporting federations, team staff and athletes
7. Sports team care and sports event medical management	7.1 Roles of the SEM physician in the team environment	 7.1.1 Appropriate roles a SEM physician may be required to fulfil in the team environment in addition to clinical skills 7.1.2 Inappropriate roles that a SEM physician may be asked to fulfil in a team environment
	7.2 The Olympic movement medical code on the ethical treatment of athletes	 7.2.1 The Olympic movement medical code as an appropriate ethical framework when providing medical care for athletes 7.2.2 The role of a SEM physician in leading education on key aspects of the Olympic movement medical code
	 7.3 Medical evaluation of athletes and event participants (Please note title change compared to the initial paper) 	 7.3.1 Assessment of the need for, and required level of, pre-season/pre-event medical evaluation of athletes, as well as the strengths and limitations of such evaluations 7.3.2 Implementation of pre-season and pre-event athlete health evaluation programs
	7.4 Pre-season/pre-event medical organisation	 7.4.1 Planning and execution of a comprehensive medical support plan (including but not limited to manpower, equipment, consumables, communication etc) for sporting events - both when travelling with teams and as part of Local Organising Committee (LOC) medical team 7.4.2 Planning and execution of a comprehensive preseason / pre-event athlete information program and be involved in implementing such a program

	mont modical	7 E 1 Design and everything of a comprehensive
	ment, medical	7.5.1 Design and execution of a comprehensive
	nd facilities for	medical equipment, supplies and facilities plan
	event care	according to the specific needs of teams and events
	i/event day	7.6.1 Development of written medical action plans
medical ca	are	for sporting events
		7.6.2 Specific training requirements in the
		management of pre-hospital emergency care for
		those undertaking sporting event coverage
		7.6.3 Creation of a medical and allied health team for
		community-based events e.g. fun runs
		7.6.4 Integration of medical teams with other
		resource groups including communications teams,
		spotters, transport teams and ambulance services
7.7 Emerg	jency sports	7.7.1 A structured approach to the assessment of
medicine:	on-field	acute medical situations in a pre-hospital setting
assessmer	nt and	including but not limited to: cardiac events, acute
managem	ent of sports	allergic events, respiratory compromise,
	nd medical	hypoglycaemia, hyponatremia, hyperthermia,
conditions	S	hypothermia, drowning and collapse
		7.7.2 A structured approach (such as the DRSABCDE)
		to on field/in event acute medical and injury
		situations in a pre-hospital setting
		7.7.3 Potential risks to players, officials and medical
		teams when delivering event medical care (on-field
		and elsewhere) and mitigation of these risks
		7.7.4 A structured approach to the management of
		potential spinal injuries in a pre-hospital setting
		7.7.5 A structured approach to the management of
		airway compromise in a pre-hospital setting
		7.7.6 A structured approach to the management of
		traumatic respiratory compromise, e.g. laryngeal
		fracture, tension pneumothorax, in a pre-hospital
		setting
		7.7.7 A structured approach to the management of
		traumatic circulatory compromise e.g. haemorrhage
		from a laceration, fracture, or organ injury in a pre-
		hospital setting
		7.7.8 A structured approach to the management of
		neurological injury e.g. serious head injury or spinal
		injury in a pre-hospital setting
		7.7.9 A structured approach to the management of
		fractures and dislocations, including reduction of
		these where appropriate, in a pre-hospital setting
		7.7.10 A structured approach to the management of
		facial, dental, ENT and eye injuries in a pre-hospital
		setting
		7.7.11 A structured approach to the management of
		traumatic dermal and subdermal injuries including
		grazes, lacerations, and contusions
		Comment: The ISSEMG strongly recommends that
		the specific learning areas for this general learning
		area are learnt as a component of a structured
		practical course and revised frequently

7.8 Post season and post event review of medical care7.8.1 The value of in-season/in-event data of in the evaluation of medical care of teams a 7.8.2 The conduct of a post season/post even medical review 7.8.3 Drawing inferences and making	
care 7.8.2 The conduct of a post season/post events medical review	
medical review	
	ent
7.8.3 Drawing inferences and making	
recommendations from such reviews, in	
collaboration with other members of the at	hlete
health team	
7.9 Team travel 7.9.1 Structure and delivery of pre-travel m	edical
advice for athletes and team officials appro	
the destination, including but not limited to	
vaccinations, environmental adaptation, an	
infectious disease risks	-
7.9.2 Implementation of medical strategies	for
dealing with time zone change	
7.9.3 Development of strategies, with allied	hoalth
team members, for nutrition, recovery, and	
management during and after team travel e	
a b	
7.9.4 Appropriate medical kits for team trav	
7.9.5 The necessary permissions required as	
when travelling internationally with teams a	
those permissions may vary from country to	5
7.9.6 Liaison with local medical systems wh	en
travelling with teams internationally	
7.10 Common general 7.10.1 Diagnosis and treatment of common	
practice problems 7.10.2 Diagnosis and treatment of common	
encountered when dermatological issues	
travelling with teams 7.10.3 Diagnosis and treatment of common	allergic
reactions	
7.10.4 Diagnosis and treatment of common	
psychological issues in athletes	
7.10.5 Diagnosis and treatment of moderate	е
exacerbations of common medical problem	s such as
asthma, dysmenorrhoea, and migraine	
8. Physical activity 8.1 SEM as it relates to 8.1.1 Physiological adaptations triggered by	exposure
in challenging physical activity at altitude to increasing altitude, including respiratory,	
environments cardiovascular, haematological, renal, and s	
adaptations	•
8.1.2 The use of altitude adaptations as par	t of a
training regimen	
8.1.3 The risks of developing altitude relate	d medical
conditions in various scenarios including ski	
trekking and mountain climbing	
8.1.4 The symptoms and management of al	titude
related medical conditions including altitud	
headache, acute mountain sickness, high al	
pulmonary oedema, high altitude cerebral o	
high altitude cough, high altitude retinopat	
	iy anu
other related problems	hor
8.1. Altitude related illness as a mimic of ot	
medical conditions including but not limited	
poisoning, concussion, hypertensive crisis, t	ransient
ischaemic attack, and respiratory disease	
8.1.6 Recognise that age, pre-existing media	
conditions, and medications increase a varie	ety of risks
when exercising at altitude	

		8.1.7 Risk reduction strategies, for both individuals
		and organisations, in the prevention of altitude related medical conditions, including the optimal
		acclimatisation period and appropriate medications
	8.2 SEM as it relates to	8.2.1 Principles of heat exchange between the body
	physical activity in cold	and the surrounding environment
	environments	8.2.2 Physiological adaptations triggered by exposure
	crivitoriments	to cold
		8.2.3 Recognition and initial management of
		peripheral tissue injury caused by cold
		8.2.4 Recognition and initial management of loss of
		core temperature, including knowing the
		classifications of severity of hypothermia and how
		this alters management
		8.2.5 Additional risk factors for cold injury including
		but not limited to water immersion, wind chill,
		alcohol, age, clothing, and prescription medications
		8.2.6 The effects of cold on other medical conditions
		such as asthma
		8.2.7 Recognition and initial management of cold
		mediated immune disorders 8.2.8 Risk reduction strategies, for both individuals
		and organisations, in the prevention of cold related
		illnesses
	8.3 SEM as it relates to	8.3.1 Principles of heat exchange between the body
	physical activity in hot	and the surrounding environment
	environments	8.3.2 Physiological adaptations triggered by exposure
		to heat
		8.3.3 Recognition and initial management of
		peripheral tissue injury caused by heat
		8.3.4 Recognition and initial management of
		increased core temperature, including an
		understanding of the classifications of heat related
		illness and how this alters management
		8.3.5 Additional risk factors for heat related illness
		including but not limited to lack of acclimatisation, limited access to suitable fluids, prescription
		medication, previous heat related illness, clothing,
		age and intercurrent illness
		8.3.6 Risk reduction strategies for both individuals
		and organisations in the prevention of heat related
		illnesses
9. Specific groups	9.1 SEM as it relates to	9.1.1 Consider long term outcomes as
undertaking sport	paediatric athletes	paramount when managing sports
and exercise		injuries in children and adolescents
	(Please note title change	9.1.2 The influence of growth and maturation on
	compared to the initial	cardiovascular fitness and muscular strength
	paper	9.1.3 Age appropriate training principles
		9.1.4 Training load management during childhood
		and adolescence including signs of overtraining
		9.1.5 The problems of early sports specialisation versus the benefits of non-specialisation
		9.1.6 Osteochondroses, including traction
		apophysitis. Differentiate those with a benign course
		from those that require specific intervention to
		prevent long term disability
L	1	

1	
	9.1.7 Anterior cruciate ligament injury, prevention,
	and treatment 9.1.8 Pars interarticularis injury, prevention, and
	treatment
	9.1.9 Recognition and management of concussion in
	children and adolescents
	9.1.10 Recognition and initial management of
	diseases masquerading as sports injury including but
	not limited to juvenile inflammatory arthropathy and
	bone tumours
	9.1.11 Sport and exercise for children with chronic
	disease
9.2 SEM as it relates to	9.2.1 Physiological and biomechanical differences and
female athletes	injury risk
(Please note title change	9.2.2 Menstruation, menstrual dysfunction, and exercise
compared to the initial	9.2.3 Pregnancy and exercise
paper	9.2.4 Polycystic ovary syndrome, including the 'lean'
	form
	9.2.5 Sacroiliac joint dysfunction
	9.2.6 Breast issues relating to exercise
	9.2.7 Recognition and initial management of
	gynaecological issues presenting in a SEM context
9.3 SEM as it relates to	9.3.1 Benefits of exercise during the ageing process
ageing athletes	9.3.2 Sarcopenia and osteoporosis 9.3.3 Increased risk of cardiovascular events
(Please note title change	9.3.4 Influence of medication on exercise capacity
compared to the initial	9.3.5 Limitations on exercise capacity caused by
paper	intercurrent disease
<i>F</i> - <i>F</i>	9.3.6 Sport and exercise in older athletes with chronic
	disease
9.4 SEM as it relates to	9.4.1 Current concepts in classification of athletes
athletes with a disability	with disabilities
	9.4.2 Critical role of interdisciplinary health care
(Please note title change	9.4.3 Spinal cord injured athletes, urinary tract issues
compared to the initial	including infection
paper	9.4.4 Spinal cord injured athletes, the influence of injury level on heat tolerance and cardiac output
	9.4.5 Spinal cord injured athletes, skin, and wound
	care
	9.4.6 Spinal cord injured athletes, autonomic
	dysreflexia, spontaneous and intentional
9.5 SEM as it relates to	9.5.1 Injury prevention and first aid kits for these
extreme and adventure	athlete groups
sport athletes	9.5.2 Specific screening protocols for these athlete
(Diasco noto titlo change	groups, where available
(Please note title change compared to the initial	9.5.3 The increased risk of injuries and environment related medical problems in these athlete groups
paper	9.5.4 The possible link between extreme cardiac
	loads and the potential for longer term cardiac issues
	such as conduction problems
	9.5.5 The value of learning first aid and the use of
	safety devices, such as personal locator beacons, in
	these athlete groups

		Comment: Wilderness medicine may be included as an advanced specific learning area
10. Intrinsic skills of a SEM physician	10.1 Communication	10.1.1 Methods of conveying SEM messages to individuals, teams, and sporting organisations 10.1.2 Methods for effective communication with medical and allied health professionals on clinical cases in both non-emergency and emergency situations 10.1.3 Methods of facilitating shared medical decision making, including athletes, coaches, and
		where appropriate other stakeholders
	10.2 Collaboration	10.2.1 Work effectively in groups including medical teams, sporting teams and research teams 10.2.2 Recognise and utilise the skill sets of other professionals
	10.3 Leadership and management	 10.3.1 The leadership roles a SEM physician 10.3.2 Leadership and management skills 10.3.3 Methods of developing leadership skills, and their use in interdisciplinary situations, including the utilisation of feedback for skill improvement
	10.4 Health advocacy	 10.4.1 Skills required when acting as a health advocate for individuals 10.4.2 Skills required when acting as a health advocate with teams and sporting organisations 10.4.3 Skills required when acting as a health advocate for the community, including charities and health promotion organisations, on SEM issues
	10.5 Research, teaching and learning	 10.5.1 Skills required for the interpretation of research publications 10.5.2 Skills required for teaching at both community and professional level 10.5.3 The need for, and active participation in, lifelong professional learning 10.5.4 Skills required to acquire, appraise, and apply evidence to individual patient care 10.5.5 Mentoring skills for others involved in SEM
	10.6 Professionalism	 10.6.1 Recognition of the limits of a personal skill set 10.6.2 Appropriate professional boundaries when dealing with patients (including athletes not under direct care), sporting administrators and members of medical teams 10.6.3 National professional reporting requirements 10.6.4 Participation in maintenance of professional standards programs
	10.7 Ethics	 10.7.1 Always act in the best interests of the patient, both short and long term 10.7.2 Potential conflicts of interest when dealing with sporting organisations 10.7.3 Potential conflicts of interest when dealing with commercial organisations, including, but not limited to, pharmaceutical companies 10.7.4 Reporting requirements around issues of athlete welfare, safety, and inappropriate behaviour of staff, colleagues, or parents to the appropriate authorities

	10.8 Cultural, religious and LGBTQI awareness and	Comment: ISSEMG recognises that in some circumstances, notably pre-contract medical screening examinations, a SEM physician will be acting primarily for an organisation rather than for the athlete. This is acceptable provided national regulatory frameworks on medical information sharing are adhered to and the process is transparent 10.8.1 Advocacy for safe inclusive sport and exercise programs
	safety (Please note title change compared to the initial paper	10.8.2 Recognition and reporting of inappropriate behaviours, such as bullying, in the SEM context 10.8.3 Recognition of and respect for diversity in the SEM context
11. Extrinsic skills of a SEM physician	11.1 Perform a comprehensive examination of the musculoskeletal and neurological systems and interpret the findings at an advanced level	 11.1.1 Assessment of each anatomical region in terms of musculoskeletal integrity, function, and variation 11.1.2 Assessment of each anatomical region and globally in terms of neurological integrity, function, and variation 11.1.3 The examination features that help differentiate musculoskeletal injury from musculoskeletal disease 11.1.4 Sensitivity and specificity of common musculoskeletal examination special tests 11.1.5 Positive and negative predictive values of commonly used musculoskeletal examination special tests 11.1.6 The biomechanical consequences of an injury or insufficiency of one musculoskeletal anatomical areas
	11.2 Perform a sport- specific medical and musculoskeletal screening examination	 11.2.1 Generic sports medicine evaluation examinations of an athlete 11.2.2 Sport specific evaluation programs and the development of such programs 11.2.3 Additional testing appropriate for sporting organisations and athletes based on needs 11.2.4 Vaccinations appropriate for sporting organisations and athletes appropriate for their needs, where necessary enlisting the assistance of infectious disease specialists 11.2.5 The purposes and potential harms of sport specific medical and musculoskeletal evaluations including communication of this information
	11.3 Perform advanced life support in non-hospital environments	 11.3.1 Basic CPR, the use of an automated external defibrillator and advanced life support 11.3.2 Appropriate review cycles for these skills Comments: The ISSEMG believes these skills should
	11.4 Provide effective immediate medical care for on-field injuries and medical events	be mandatory in training 11.4.1 Have and maintain specialist skills in providing care as listed in the general learning area 'Emergency sports medicine: On field assessment and management of sports injuries and medical conditions' 11.4.2 Ongoing cycles of training in on-field care

	11 5 Daufaura	
	11.5 Perform concussion	11.5.1 Current and emerging tests available for
	screening examinations,	concussion screening, including their validity and
	baseline, and post-injury,	weaknesses
	and interpret the results	11.5.2 Administration of appropriate concussion
		screening tests including, but not limited to, the current SCAT test
		11.5.3 Clinically significant variations between
		baseline and post head injury concussion screening
		tests
		11.5.4 Assessment of concussion using a combination
		of clinical acumen and concussion screening tests
		11.5.5 Resources and processes for the assessment of
		concussion in children
	11.6 Interpret radiological	11.6.1 Advanced skills in interpreting musculoskeletal
	and other investigations	images in the following radiological modalities: X-Ray,
	relating to SEM at an	CT scanning, MRI scanning and musculoskeletal
	advanced level	ultrasound
		11.6.2 Advanced skills in interpreting laboratory tests
		pertinent to the care of athletes
		11.6.3 The role, utility, and general interpretation of
		isotope bone scans
		11.6.4 The role, utility, and general interpretation of
		DXA scans and other modalities of determining bone
		health
		11.6.5 The role, utility, and timing of
		electrophysiological tests in diagnosing peripheral
		neurological and neuromuscular issues
		Comment: In this circumstance advanced skill means
		a skill level slightly below a specialist clinician in that
		field e.g. a radiologist, but sufficient to confidently
		interpret an investigation without recourse to
		another specialist in all but complex cases
	11.7 Interpret ECG findings	11.7.1 The performance of a standard 12 lead ECG
	in an athlete with reference	11.7.2 ECG findings consistent with 'athlete heart'
	to current guidelines	11.7.3 ECG findings of concern in an athlete
	-	11.7.4 The further investigation of ECG findings of
		concern in an athlete
		11.7.5 Recognition of the need for a sports
		cardiologist opinion in many cases
		11.7.6 The indications for, and principles of
		performing and interpreting, a stress ECG
	11.8 Inject a variety of	11.8.1 Safe injection practices including informed
	joints and soft tissues	consent
	without radiological	11.8.2 The purpose and safety of the various
	guidance	injectable substances pertinent to SEM
		11.8.3 Have the knowledge required to determine
		whether a guided or unguided injection is more
		appropriate
		11.8.4 Safe injection of ankle, knee, elbow and
		shoulder joints and associated peri-articular tissues
		11.8.5 Safe injection of soft tissues including tendon,
		peri-tendon, muscle, and bursae where it is
1		appropriate to inject without radiological guidance

11.9 Prescribe advanced	11.9.1 Appropriate braces to assist in injury
protective braces	prevention, acute injury management and long-term
	protection of the musculoskeletal system
11.10 Advanced skills	11.10.1 Methods of taping joints, tendons and
	muscles for injury prevention and treatment
	11.10.2 Interpretation of simple video analysis of a
	variety of sporting skills including running gait
	11.10.3 Performance and interpretation of a targeted
	ultrasound examination for a peripheral
	musculoskeletal problem
	11.10.4 Injection techniques for a variety of joints
	and soft tissues using ultrasound guidance
	11.10.5 Performance and interpretation of the
	findings of a resting and exercise lung function test
	11.10.6 Performance and interpretation of a stress
	ECG

Discussion

Specialty training in SEM is evolving, and various training models exist. The ISSEMG syllabus can be adapted to a variety of contexts, including training systems where SEM specialisation is gained as an additional component of a primary specialty. In such circumstances components of the syllabus may have already been covered during training in the primary specialty. The breadth and depth of the syllabus presented is substantial and it should be evident that the training of specialist SEM physicians requires significant resources and time. The ISSEMG recognises that some of the specific learning areas listed cover areas that are still in flux in terms of our level of knowledge. As such the ISSEMG syllabus should be treated as a living document by national medical organisations that guide training in the medical speciality of SEM. They will need to refine and adapt the syllabus to their needs and consider evolving knowledge.

Developing a medical specialty curriculum from a syllabus is a significant undertaking. Curriculum developers must have a deep understanding of the relevant national (or local) medical system and available resources, the health priorities of the given system, the medical pre and post graduate education processes available in that system, and the proposed scope of practice of the new specialty. For the actual development of a curriculum several other fundamentals are required. These include: 1. a curriculum document, based on a syllabus, that clearly details the relevant learning outcomes required to cover the learning areas of the syllabus, 2. teaching and learning methods designed specifically to satisfy the requirements of each learning area, mapped to the curriculum 3. validated formative and summative assessment processes blueprinted to the curriculum document, 4. a comprehensive outline of the training process, which in SEM typically includes items such as the usual training duration required, necessary clinical exposure, sports team and event coverage, research and the reporting requirements of trainees and supervisors, 5. access to suitable training instructors and training positions, 6. the ability to develop doctors who are not just medical experts but also have competence in other fundamentals including, but not limited to communication, collaboration, scholarship, leadership and health advocacy and 7. a cycle of review and renewal of the curriculum.

Conclusion

The ISSEMG has developed a syllabus for the medical specialty of SEM. This syllabus will be of value to national medical organisations developing SEM specialty or subspecialty training programs and may inform benchmarking of current training programs. This syllabus will contribute to the future international development of the medical specialty of SEM internationally. No further publications are planned by the ISSEMG.

Statements:

Competing interests None

Contributorship All listed authors have made substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data. Additionally, they have been involved in the drafting or critical review and have approved the final version

Acknowledgements The following people were additional collaborators in this project, F.J.G. Backx, Bert Fields, Maarten Koornneef, Els Stolk

Funding informationThere are no funders to report for this submissionEthics approvalNot applicableData sharingNot applicable

References

- 1. Humphries, D., R. Jaques, and H.P. Dijkstra, *A Delphi developed syllabus for the medical specialty of sport and exercise medicine.* British Journal of Sports Medicine, 2018. 52(8): p. 490-492.
- 2. WHO, Global action plan on physical activity 2018–2030: more active people for a healthier world. 2018, Geneva.